BMAL1 and neoplasm: In this context, pharmacologically restoring BMAL1 expression led to suppression of N-MYC-driven lipogenesis and diminished tumor growth [38], suggesting that N-MYC and CLOCK-BMAL1 may drive opposing metabolic programs in these cancer cells.